Indapamide retard 1.5 mg long-acting tablets 30

$20.30
Size chart
Women's clothing size
SizeXSSML
Euro 32/34 36 38 40
USA 0/2 4 6 8
Bust(in) 31-32 33 34 36
Bust(cm) 80.5-82.5 84.5 87 92
Waist(in) 24-25 26 27 29
Waist(cm) 62.5-64.5 66.5 69 74
Hips(in) 34-35 36 37 39
Hips(cm) 87.5-89.5 91.5 94 99
How To Measure Your Bust

With your arms relaxed at your sides, measure around the fullest part of your chest.

How To Measure Your Waist

Measure around the narrowest part of your natural waist, generally around the belly button. To ensure a comfortable fit, keep one finger between the measuring tape and your body.

Volume discounts

Quantity Unit discount You Save
2 33% $13.40
3 38% $23.14
4 46% $37.35
 Customer ratings and reviews
Nobody has posted a review yet
in this language
Reference:
Love0
Add to compare0
Add to wishlist
Description
Country
Russia
Active ingredient
Indapamide
Dosage
1,5mg
Composition

Active substance: indapamide 1.5 mg.

Excipients: hypromellose - 77.36 mg, lactose monohydrate (milk sugar) - 119.14 mg, silicon dioxide colloidal (aerosil) - 1 mg, magnesium stearate - 1 mg, opadrai II (hypromellose - 2.24 mg, lactose monohydrate - 2.88 mg, polyethylene glycol - 800 μg, titanium dioxide - 2.08 mg) - 8 mg.

Pharmacological properties

Antihypertensive agent, thiazide-like diuretic with moderate in strength and long-lasting action, derivative of benzamides. It has moderate saluretic and diuretic effects, which are associated with the blockade of the reabsorption of sodium, chlorine, hydrogen ions, and to a lesser extent potassium ions in the proximal tubules and the cortical segment of the distal tubule of the nephron. Vasodilating effects and a decrease in the total peripheral resistance of blood vessels are based on the following mechanisms: reducing the reactivity of the vascular wall to norepinephrine and angiotensin II; increased synthesis of prostaglandins with vasodilating activity; inhibition of the flow of calcium ions into the smooth muscle walls of blood vessels.

Reduces the tone of the smooth muscles of the arteries, reduces the overall peripheral resistance of blood vessels. Helps to reduce hypertrophy of the left ventricle of the heart. In therapeutic doses, it does not affect lipid and carbohydrate metabolism (including in patients with concomitant diabetes mellitus).

The antihypertensive effect develops at the end of the first / beginning of the second week with constant intake of the drug and persists for 24 hours against the background of a single dose.

Indications for use
Arterial hypertension.
Contraindications
  • acute violation of cerebral circulation;
  • severe impairment of the kidneys (creatinine clearance less than 30 ml / min) and / or liver (including with hepatic encephalopathy);
  • hypokalemia;
  • pregnancy;
  • lactation period;
  • age up to 18 years (efficacy and safety have not been established);
  • hypersensitivity to indapamide, other sulfonamide derivatives or other components of the drug.

These tablets contain lactose monohydrate (milk sugar), in this regard, the drug should not be taken by patients with rare hereditary diseases, such as lactose intolerance, lactase deficiency or glucose-galactose malabsorption.

The drug is used with caution in diabetes mellitus, hyperuricemia (especially accompanied by gout and urate nephrolithiasis), hyponatremia and other disorders of the water-electrolyte balance, moderate hepatic and / or renal failure, chronic heart failure, hyperparathyroidism, in patients with an increased QT interval on the ECG or receiving combined therapy, as a result of which it is possible to prolong the QT interval (astemizole, erythromycin (intravenously), pentamidine, sultopride, terfenadine, vincamine (IV), antiarrhythmic drugs IA class (quinidine, disopramide) and class III (amiodarone, bretile tosylate).

Use in pregnancy and lactation

The drug is not recommended for use during pregnancy, because diuretics can cause fetoplacental ischemia with the risk of developing fetal hypotrophy. Indapamide can not be used to treat physiological edema during pregnancy.

Indapamide is excreted in breast milk. Given the possibility of adverse events in infants, breastfeeding during treatment is not recommended.

Use in case of impaired liver function

Contraindicated:

  • severe impairment of liver function (including with hepatic encephalopathy).

In patients with hepatic insufficiency with the appointment of thiazide-like diuretics, the development of hepatic encephalopathy is possible, especially in violation of the water-electrolyte balance. With its development, the use of diuretics should be discontinued.

Use in renal dysfunction

Contraindicated:

  • severe renal dysfunction (creatinine clearance less than 30 ml / min).

Thiazide and thiazide-like diuretics are effective, to the full extent, only in patients with normal or slightly reduced (plasma creatinine in adults less than 25 mg / l or 220 μmol / l) renal function.

Severe hypovolemia can lead to the development of acute renal failure (decreased glomerular filtration rate), which may be accompanied by an increase in concentration of urea and creatinine in the blood plasma. With normal renal function, transient functional renal failure, as a rule, passes without consequences. With existing renal failure, the patient's condition may worsen.

Use in children

Contraindicated:

  • age up to 18 years (efficacy and safety have not been established).
Use in elderly patients
In elderly patients, plasma creatinine concentration should be monitored, taking into account age, body weight and sex, the drug can be used in elderly patients with normal or slightly impaired renal function.
Special instructions

Impaired liver function

In patients with hepatic insufficiency with the appointment of thiazide-like diuretics, the development of hepatic encephalopathy is possible, especially in violation of the water-electrolyte balance. With its development, the reception Diuretics should be discontinued.

Photosensitivity

When using thiazide-like diuretics, cases of the development of photosensitivity reactions have been noted. In case of their development, the drug should be discontinued. Against the background of therapy with Indapamide retard, it is necessary to protect open areas of the body from exposure to sunlight and artificial ultraviolet radiation.

Water-electrolyte balance

  • the content of sodium ions in the blood plasma: all diuretic drugs can cause hyponatremia. The content of sodium ions in the blood plasma should be measured before starting treatment with Indapamide retard, and then regularly during the treatment period. Determination of the content of sodium ions in the blood plasma should be carried out before starting therapy with Indapamide retard, as well as during the period of therapy. It is important to regularly monitor the content of sodium ions in the blood plasma, because initially hyponatremia can be asymptomatic. Most careful monitoring of the content of sodium ions is indicated for elderly patients and patients with cirrhosis of the liver.
  • the content of potassium ions in the blood plasma: the greatest risk in the treatment of thiazide-like diuretics is hypokalemia. Particular attention should be paid to the prevention of hypokalemia (less than 3.4 mmol / l) in the following cases: debilitated patients and / or receiving other therapy (antiarrhythmic drugs and drugs that can prolong the QT interval on the ECG), in the elderly, patients with cirrhosis of the liver, peripheral edema and ascites; with coronary heart disease and chronic heart failure.

Hypokalemia in such patients increases the toxic effect of cardiac glycosides and increases the risk of developing arrhythmia.

The high-risk group also includes patients with an extended QT interval on the ECG. Hypokalemia is a predisposing factor in the occurrence of severe arrhythmia, and especially arrhythmias of the "pirouette" type, which can be fatal.

In all the cases described, it is necessary to regularly monitor the potassium content in the blood plasma. The first determination of the potassium content in the blood plasma should be carried out during the first week of therapy with Indapamide retard.

If hypokalemia is detected, appropriate therapy should be performed.

  • plasma calcium ion content: Thiazide-like and thiazide diuretics can reduce the excretion of calcium ions by the kidneys, leading to minor and/or temporary hypercalcemia. Severe hypercalcemia while taking the drug Indapamide retard may be a consequence of previously undiagnosed hyperparathyroidism.

It is necessary to cancel the use of diuretics before examining the function of the parathyroid glands.

  • plasma glucose concentration: in patients with diabetes mellitus, especially in the presence of hypokalemia, it is necessary to control the concentration of glucose in the blood plasma.
  • uric acid: in patients with hyperuricemia may increase the frequency

the occurrence of attacks or exacerbation of the course of gout.

Kidney function and diuretic drugs

Thiazide and thiazide-like diuretics are effective, to the full extent, only in patients with normal or slightly reduced (plasma creatinine in adults less than 25 mg / l or 220 μmol / l) renal function.

Severe hypovolemia can lead to the development of acute renal failure (decreased glomerular filtration rate), which may be accompanied by an increase in the concentration of urea and creatinine in the blood plasma. With normal renal function, transient functional renal failure, as a rule, passes without consequences. With existing renal failure, the patient's condition may worsen.

Elderly patients

Regular monitoring of creatinine concentration and potassium content in the blood plasma is recommended, taking into account the patient's age, body weight and sex. Indapamide retard can be prescribed to elderly patients with preserved or slightly impaired renal function (QC above 30 ml / min).

Athletes

Indapamide retard can give a positive result during doping control.

Influence on the ability to drive vehicles and control mechanisms

The use of indapamide retard does not lead to a violation of psychomotor reactions. However, in some patients, in response to a decrease in blood pressure, various individual reactions may develop, especially at the beginning of therapy or when other antihypertensive drugs are added to the therapy. In this regard, at the beginning of treatment with Indapamide retard, it is not recommended to drive vehicles or other complex mechanisms that require increased attention.

Usage and doses

Inside, without chewing, drinking a sufficient amount of liquid, regardless of food intake, mainly in the morning at a dose of 1.5 mg (1 tablet) / day.

If after 4-8 weeks of treatment the desired therapeutic effect is not achieved, it is not recommended to increase the dose of the drug (the risk of side effects increases without enhancing the antihypertensive effect). Instead, it is recommended to include another antihypertensive drug that is not a diuretic in the drug treatment regimen. In cases where treatment should begin with taking two drugs, the dose of Indapamide retard remains equal to 1.5 mg in the morning once a day.

In elderly patients, plasma creatinine concentration should be monitored, taking into account age, body weight and sex, the drug can be used in elderly patients with normal or slightly impaired renal function

Overdose

Symptoms: nausea, vomiting, weakness, disturbance gastrointestinal functions (nausea, vomiting), water-electrolyte disorders, a pronounced decrease in blood pressure, dizziness, drowsiness, confusion, respiratory depression, polyuria, oligouria up to anuria, in patients with impaired liver function, the development of hepatic coma is possible.

Treatment: gastric lavage and / or the appointment of activated charcoal, followed by the restoration of normal water-electrolyte balance, symptomatic therapy. There is no specific antidote.

Side effects

Most adverse reactions (laboratory and clinical indicators) are dose-dependent.

The frequency of adverse reactions that can be caused by thiazide-like diuretics, including indapamide, is given in the form of the following gradations: very often (>1/10); often (>1/100, <1/10); infrequently (>1/1000, <1/100); rarely (>1/10,000, <1/1000); very rarely (<1/10,000); unspecified frequency (frequency not can be calculated from available data).

From the hematopoietic system: very rarely - thrombocytopenia, leukopenia, agranulocytosis, aplastic anemia, hemolytic anemia.

From the central nervous system: rarely - dizziness, fatigue, headache, paresthesia.

From the cardiovascular system: very rarely - arrhythmia, decreased blood pressure.

From the digestive system: infrequently - vomiting; rarely - nausea, constipation, dry mouth; very rarely - pancreatitis.

From the urinary system: very rarely - renal failure.

From the liver and biliary tract: very rarely - impaired liver function; unspecified frequency - the possibility of developing hepatic encephalopathy in the case of liver failure.

From the skin: hypersensitivity reactions, mainly dermatological, in patients with a predisposition to allergic and asthmatic reactions; often - maculopapular rash; infrequently - hemorrhagic vasculitis; very rarely - angioedema and / or urticaria, toxic epidermal necrolysis, Stevens-Johnson syndrome; unspecified frequency - possible deterioration in the presence of an acute form of disseminated lupus erythematosus. Cases of photosensitivity are described.

Laboratory indicators: in clinical trials, hypokalemia (potassium content in the blood plasma ≤3.4 mmol / l) was observed in 10% of patients and 3.2 mmol / l in 4% of patients after 4-6 weeks of treatment. After 12 weeks of therapy, the level of potassium in the blood plasma decreased, on average, by 0.23 mmol / L. Very rarely - hypercalcemia; unspecified frequency - hypokalemia, hyponatremia, accompanied by hypovolemia, dehydration and orthostatic hypotension. Simultaneous loss of chlorine ions can lead to compensatory metabolic alkalosis, but the incidence of alkalosis and its severity is not significant; increased levels of uric acid and glucose in the blood plasma.

Storage conditions

In a dry, dark place at a temperature not exceeding 25 ° C. Keep out of the reach of children.

Shelf life - 3 years. Do not use after the expiry date which is stated on the carton.

Read more
Product Details

Data sheet

Brand
Ozon
service_future
otc_02
Dosage form
long-acting tablets
Dosage
10 mg
INN
None
Number of tablets
30
INN Russian
None
Reviews
No comments
 Reviews

Be the first to write your review !

Menu

Settings

Create a free account to save loved items.

Sign in

Create a free account to use wishlists.

Sign in